The FiberLock instrument uses a reciprocating needle to push implant fibers into the underlying soft tissue, securing the patch across the entire patch–tendon interface. The result, according to ZuriMed’s website, is mechanical augmentation — a strong, interwoven network between the patch and tendon tissue.
“ZuriMed has developed a differentiated technology that addresses an important clinical need within shoulder care,” Andy Pierce, Stryker’s group president of MedSurg and Neurotechnology, said in a news release. “We are excited about the opportunity to add the FiberLocker System to Stryker’s portfolio. This acquisition reflects our continued commitment to advancing innovation and improving patient outcomes.”
Portage, Michigan–based Stryker and Zurich, Switzerland–based ZuriMed did not disclose the deal size. The two companies will continue to operate as separate entities until the transaction closes, subject to customary closing conditions.
